Advice

following a full submission:

adalimumab (Humira®) is accepted for use within NHS Scotland.

Indication under review: treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Adalimumab, compared to placebo, improves symptoms of severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis in adults.

Adalimumab should be prescribed in accordance with Assessment in Spondyloarthritis International Society (ASAS) guidance.

Download detailed advice141KB (PDF)

Download

Medicine details

Medicine name:
adalimumab (Humira)
SMC ID:
858/13
Indication:
For the treatment of adults with severe axial spondyloarthritis without radiographic evidence of ankylosing spondylitis (nr-axSpA) but with objective signs of inflammation by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).
Pharmaceutical company
AbbVie Ltd
BNF chapter
Musculoskeletal and joint diseases
Submission type
Full
Status
Superseded
Date advice published
08 April 2013
Additional notes

NICE MTA Advice:  SMC Advice is superseded by National Institute for Health and Care Excellence (NICE) Multiple Technology Appraisal (MTA)